February 2023 Newsletter
New Animal Models Humanized Immune-Checkpoint Mice Catalog Number Product 111243 B-hICAM3 mice 111960 B-hCD3E/h4-1BB/HLA-A2.1 mice 112713 B-hCD3EDG/hCD28/hTROP2 mice 112712 B-hCD3EDG/hCD28/hCD20 mice 112259 B-hNKP46 mice(CB-17 SCID)…
Read more
Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs
Beijing, China and Tokyo, Japan, July 21, 2022 – February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co.,…
Read more
Biocytogen/Eucure Biopharma Announce First Patient Dosed in Phase II Clinical Trial of YH003 Combination Therapy as a First-Line Treatment for Mucosal Melanoma
Beijing, China, July 12, 2022 -- Biocytogen subsidiary Eucure Biopharma announced that the first patient has been dosed in a phase II clinical trial (No.…
Read more
Tumor Models Boston 2022
Attend the meeting Talk to us Meet our expert scientists to learn about our recent advances in preclinical drug evaluation, which includes new humanized animal…
Read more
EACR 2022 Congress
EACR 2022 is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest…
Read more
Biocytogen Europe Innovation Center Team to Present at AET-EU 2022, Introducing Project Integrum, TCR-mimic Platform and YH012
Beijing and Heidelberg, June 3, 2022 -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") today announced 3 poster presentations for two novel fully human antibody platforms…
Read more
Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Beijing, China, May 24, 2022 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), today announced that it will…
Read more
Immunology 2022
Poster Session Poster number: P620 Title: RenMice™ HiTS Platform Enables Identification of Novel Therapeutic Antibodies Date: Sunday, May 8, 2022 Time: 2:30 PM - 3:45 PM…
Read more
Biocytogen Enters into Antibody Agreement with Merck
BEIJING, CHINA, [April 29, 2022] – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck…
Read more
Biocytogen Signs RenMab™/RenLite® Licensing Agreement with BeiGene
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene (Beijing) Co., Ltd. ("BeiGene") (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) for licensing Biocytogen’s fully…
Read more